While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

Nearly three quarters of U.S. adults are overweight or obese, according to a sweeping new study. The findings have ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

"For healthcare providers, these findings suggest that anti-obesity medications may offer dual benefits," one doctor reports ...

The rise in type 2 diabetes cases globally presents opportunities for growth in the market for GLP-1 drugs like Ozempic and ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...

GLP-1 drugs have been linked to numerous potential health benefits like treatment of existing conditions including heart ...

With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of ...

Similar to Lilly's weight loss treatments (Mounjaro and Zepbound), VK2735 is a dual glucagon-like peptide ... it's important ...

The move comes after the FDA took tirzepatide, the key ingredient in Eli Lilly’s (LLY) diabetes drug Mounjaro and weight-loss ...